<DOC>
	<DOCNO>NCT01580878</DOCNO>
	<brief_summary>The primary objective study determine comparability safety efficacy generic Butenafine Hydrochloride Cream , 1 % ( test product ) Lotrimin Ultra® ( reference list drug ) subject interdigital tinea pedis . It also determine whether efficacy two active treatment superior vehicle cream ( placebo ) .</brief_summary>
	<brief_title>Evaluate Safety &amp; Bioequivalence Generic Butenafine Cream &amp; Lotrimin Ultra® &amp; Compare Both Vehicle Control Treatment Interdigital Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Clotrimazole</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Butenafine</mesh_term>
	<criteria>Willing &amp; able provide &amp; understand write informed consent Healthy male nonpregnant , nonlactating female least 18 year age old Clinical diagnosis tinea pedis lesion localize interdigital space predominantly interdigital may extend area Tinea pedis provisionally confirm baseline positive potassium hydroxide ( KOH ) wet mount preparation show segmented fungal hypha Has sum clinical sign symptom score target lesion least 4 , include minimum score 2 erythema &amp; minimum score 2 scaling pruritus Currently general good health clinically significant disease Willing able understand comply study requirement Women childbearing potential must negative urine pregnancy test willing use acceptable form birth control study Females pregnant , breastfeeding , plan pregnancy , agree use acceptable form birth control study Confluent , diffuse moccasintype tinea pedis entire plantar surface Presence infection foot disease might confound treatment evaluation History dermatophyte infection unresponsive antifungal drug Known hypersensitivity Butenafine Hydrochloride component study medication Use antipruritic , topical systemic corticosteroid , antibiotic antifungal therapy , oral terbinafine itraconazole , immunosuppressive medication radiation therapy recently indicate washout period Current oral , vaginal , mucocutaneous candidiasis Current bacterial skin infection , secondary cellulitis , lymphangitis , pyoderma Presence current condition require systemic antimicrobial antifungal therapy Uncontrolled diabetes mellitus , peripheral vascular disease , chronic venous stasis , significant condition Current severe onychomycosis Any clinically significant condition situation , condition study , would interfere study evaluation participation Use investigational drug device within 30 day sign Informed Consent Form ( ICF ) Current participation clinical study Consumes excessive amount alcohol , abuse drug , condition would compromise compliance Previous participation study Subjects past history tinea pedis lack response antifungal therapy Subjects Investigator 's opinion would noncompliant Employees direct relative employee study center Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Butenafine Hydrochloride Cream , 1 %</keyword>
	<keyword>Lotrimin Ultra® Cream , 1 %</keyword>
	<keyword>Interdigital Tinea Pedis</keyword>
	<keyword>Safety Bioequivalence</keyword>
</DOC>